249 related articles for article (PubMed ID: 7372221)
1. [The use of allopurinol in long-term treatments for optimal effect].
Fenner H
Fortschr Med; 1980 Mar; 98(10):(373-6). PubMed ID: 7372221
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].
Dunky A; Nitsche V; Eberl R
Wien Klin Wochenschr; 1981 Jan; 93(2):65-8. PubMed ID: 7245774
[TBL] [Abstract][Full Text] [Related]
4. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
Gröbner W; Walter-Sack I; de Vries JX
Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
[TBL] [Abstract][Full Text] [Related]
5. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
6. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
7. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
8. Oxipurinol therapy in allopurinol-allergic patients.
Earll JM; Saavedra M
Am Fam Physician; 1983 Nov; 28(5):147-8. PubMed ID: 6637745
[No Abstract] [Full Text] [Related]
9. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
10. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
Lach HJ; Bader B; Schnitker J; Harries EH
Arzneimittelforschung; 1982; 32(1):76-9. PubMed ID: 7199345
[TBL] [Abstract][Full Text] [Related]
12. Drugs in the treatment of hyperuricemia.
Elion GB
Adv Nephrol Necker Hosp; 1974; 3():51-7. PubMed ID: 4219708
[No Abstract] [Full Text] [Related]
13. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
14. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Matzkies F
Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
[TBL] [Abstract][Full Text] [Related]
15. Effect of allopurinol in gouty patients given long term corticotherapy.
Auscher C; Amor B; Brouilhet H; Pasquier C; Delbarre F
Biomedicine; 1974 Nov; 21(11):448-51. PubMed ID: 4464994
[No Abstract] [Full Text] [Related]
16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
18. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
19. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
[TBL] [Abstract][Full Text] [Related]
20. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji M
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
